Suspected intra-articular soft-tissue tumours and tumour-like lesions: Performance of image-guided core needle biopsy

2021 ◽  
Vol 135 ◽  
pp. 109469
Author(s):  
Syed Ehtasham Junaid ◽  
Syed Bilal ◽  
Asif Saifuddin
2016 ◽  
Vol 46 (8) ◽  
pp. 1173-1178 ◽  
Author(s):  
Terrence Metz ◽  
Amer Heider ◽  
Ranjith Vellody ◽  
Marcus D. Jarboe ◽  
Joseph J. Gemmete ◽  
...  

2009 ◽  
Vol 35 (11) ◽  
pp. 1210-1211
Author(s):  
Yassar Qureshi ◽  
D. Strauss ◽  
A. Hayes ◽  
J. Thomas

2010 ◽  
Vol 20 (11) ◽  
pp. 2740-2748 ◽  
Author(s):  
Armanda De Marchi ◽  
◽  
Elena Maria Brach del Prever ◽  
Alessandra Linari ◽  
Simona Pozza ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e22521-e22521
Author(s):  
Andrew Samoyedny ◽  
Lisa States ◽  
Emma Alai ◽  
Abhay Srinivasan ◽  
John M. Maris ◽  
...  

e22521 Background: Relapsed and refractory neuroblastoma (NBL) is a prime target for novel therapies targeting specific mutations. The genomic landscape of NBL can change between time of initial diagnosis and relapse, necessitating subsequent biopsy and next generation sequencing (NGS) to detect mutations within the relapsed neoplasm. Tissue of insufficient quality and quantity leads to specimen failure during NGS. Thus the goal of this study is to review core needle biopsy for relapsed and refractory NBL in a pediatric interventional radiology department and explore factors that enhance biopsy adequacy. Methods: Retrospective review of clinical records and images for 66 patients (36M, 30F) with median age 8.7 years (range 0.9 – 49.3 y) who underwent 95 biopsies (55 bone, 40 soft tissue) over a 12-year period. Results: Biopsy yield for neuroblastic tissue from 123I mIBG-avid masses was 89.7% overall, 84.9% in bone, and 91.6% in soft tissue. 87/95 masses were mIBG-avid; 2 non-avid masses were NBL-positive (but also 18F-FDG avid). 48/59 samples sent for NGS were adequate for analysis (81.4%); bone and soft tissue biopsies did not differ in adequacy (77.1% vs 87.5%, p = 0.32). Tumor cell percent (TC%) for adequate samples was 49.9% vs 11.1% for NGS failures (p = 0.0003). Number of needle passes performed in bone and soft tissue lesions was positively correlated with NGS adequacy (Bone: r2= 0.68, Soft: r2= 0.33). In bone and soft tissue, adequate biopsies tended towards higher mean needle passes than inadequate ones (Bone: 5.1 vs 3.4, p = 0.0582) (Soft: 10.5 vs 4.7, p = 0.0428). Total needle volume passed into a soft tissue mass (calculated as inner needle cylindrical volume * # of passes) was higher in the “adequate” vs “inadequate” group (0.20 cm3 vs 0.05 cm3, p = 0.0004). Lesion mIBG avidity was quantified with a ratio of lesion:liver SUV; this mIBG SUV ratio was positively correlated with TC% (R2 = 0.55, N = 14). Using a linear regression line, a TC% of 50% (the mean value for samples adequate for NGS) corresponded to an SUV ratio of 2.89. The rate of minor complications (requiring only nominal therapy) was 7/95 (7.4%). The rate of major complications (requiring longer hospital stay) was 1/95 (1.5%). Conclusions: Image-guided core needle biopsy for relapsed and refractory NBL has a moderately high yield for procuring tumor samples adequate for NGS with a low rate of major complications. Adequate bone and soft tissue biopsies averaged >5 and >10 needle passes, respectively. An approximate lesion:liver mIBG SUV ratio of >3 may maximize specimen quality for NGS.


Radiology ◽  
2008 ◽  
Vol 248 (3) ◽  
pp. 962-970 ◽  
Author(s):  
Jim S. Wu ◽  
Jeffrey D. Goldsmith ◽  
Perry J. Horwich ◽  
Sanjay K. Shetty ◽  
Mary G. Hochman

2010 ◽  
Vol 102 (5) ◽  
pp. 523-529 ◽  
Author(s):  
D.C. Strauss ◽  
Y.A. Qureshi ◽  
A.J. Hayes ◽  
K. Thway ◽  
C. Fisher ◽  
...  

2020 ◽  
Vol 24 (06) ◽  
pp. 667-675
Author(s):  
Violeta Vasilevska Nikodinovska ◽  
Slavcho Ivanoski ◽  
Milan Samardziski ◽  
Vesna Janevska

AbstractBone and soft tissue tumors are a largely heterogeneous group of tumors. Biopsy of musculoskeletal (MSK) tumors is sometimes a challenging procedure. Although the open biopsy is still considered the gold standard for the biopsy of MSK lesions, core needle biopsy can replace it in most cases, with similar accuracy and a low complication rate. The biopsy should be performed in a tertiary sarcoma center where the multidisciplinary team consists of at minimum a tumor surgeon, an MSK pathologist, and an MSK radiologist who can assess all steps of the procedure. Several factors can influence the success of the biopsy including the lesion characteristics, the equipment, and the method used for the procedure. This review highlights some of the important aspects regarding the biopsy of the MSK tumors, with special attention to imaging a guided core needle biopsy and highlighting some of the recent advancements and controversies in the field.


Sign in / Sign up

Export Citation Format

Share Document